New guidelines on the management of Inflammatory Bowel Disease (IBD)

read more

 

Privacy Notice

read more

 

This Month's News

New guidelines on the management of Inflammatory Bowel Disease (IBD)

The British and European Crohn's and Colitis organisations have over the last 2 years published several guidelines updating the diagnosis, investigation and management of inflammatory bowel disease (IBD). Some of the important messages are listed below

  • Stopping smoking reduces the risk of disease activity in crohn's disease
  • Early use of immunomodulators in appropriate patients reduces steroid dependancy and disease relapse
  • Longterm 5 ASA may reduce the risk of cancer in the future
  • Budesonide, a  'locally acting' steroid is a useful alternative with less side-effects than prednisolone in appropriate patients
  • New drugs like biologics (anti-TNF antibodies) are useful in treating active/severe/non-responding IBD
  • Surveillance colonoscopy intervals have changed to 1,3 or 5 years rather than 2 years depending on the patients' circumstances
  • Caesarian section is preferred mode of delivery in mothers with perianal or recto-vaginal disease.

For further information on these guidelines click here

For further information on crohn's and colitis patient charity website click here